319 related articles for article (PubMed ID: 35146629)
21. Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer.
Aaltonen KE; Rosendahl AH; Olsson H; Malmström P; Hartman L; Fernö M
BMC Cancer; 2014 Nov; 14():794. PubMed ID: 25362932
[TBL] [Abstract][Full Text] [Related]
22. Targeting insulin-like growth factor in breast cancer therapeutics.
Karamouzis MV; Papavassiliou AG
Crit Rev Oncol Hematol; 2012 Oct; 84(1):8-17. PubMed ID: 22424863
[TBL] [Abstract][Full Text] [Related]
23. Demonstration of insulin-like growth factor (IGF-I and -II) receptors and binding protein in human breast cancer cell lines.
De Leon DD; Bakker B; Wilson DM; Hintz RL; Rosenfeld RG
Biochem Biophys Res Commun; 1988 Apr; 152(1):398-405. PubMed ID: 2451917
[TBL] [Abstract][Full Text] [Related]
24. Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers.
Neuhausen SL; Brummel S; Ding YC; Singer CF; Pfeiler G; Lynch HT; Nathanson KL; Rebbeck TR; Garber JE; Couch F; Weitzel J; Narod SA; Ganz PA; Daly MB; Godwin AK; Isaacs C; Olopade OI; Tomlinson G; Rubinstein WS; Tung N; Blum JL; Gillen DL
Breast Cancer Res; 2009; 11(5):R76. PubMed ID: 19843326
[TBL] [Abstract][Full Text] [Related]
25. Insulin/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer.
Mutgan AC; Besikcioglu HE; Wang S; Friess H; Ceyhan GO; Demir IE
Mol Cancer; 2018 Feb; 17(1):66. PubMed ID: 29475434
[TBL] [Abstract][Full Text] [Related]
26. A Combined Bioinformatics and Literature Based Approach for Identification of Long Non-coding RNAs That Modulate Vitamin D Receptor Signaling in Breast Cancer.
Kholghi Oskooei V; Ghafouri-Fard S; Omrani Mir D
Klin Onkol; 2018; 31(4):264-269. PubMed ID: 30541308
[TBL] [Abstract][Full Text] [Related]
27. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
28. Insulin-like growth factor - oestradiol crosstalk and mammary gland tumourigenesis.
Hawsawi Y; El-Gendy R; Twelves C; Speirs V; Beattie J
Biochim Biophys Acta; 2013 Dec; 1836(2):345-53. PubMed ID: 24189571
[TBL] [Abstract][Full Text] [Related]
29. Beneficial and detrimental aspects of miRNAs as chief players in breast cancer: A comprehensive review.
Ismail A; El-Mahdy HA; Abulsoud AI; Sallam AM; Eldeib MG; Elsakka EGE; Zaki MB; Doghish AS
Int J Biol Macromol; 2023 Jan; 224():1541-1565. PubMed ID: 36328268
[TBL] [Abstract][Full Text] [Related]
30. Role of the Mediator Complex and MicroRNAs in Breast Cancer Etiology.
Maldonado E; Morales-Pison S; Urbina F; Jara L; Solari A
Genes (Basel); 2022 Jan; 13(2):. PubMed ID: 35205279
[TBL] [Abstract][Full Text] [Related]
31. MALAT-1: LncRNA ruling miR-182/PIG-C/mesothelin triad in triple negative breast cancer.
Barsoum FS; Awad AS; Hussein NH; Eissa RA; El Tayebi HM
Pathol Res Pract; 2020 Dec; 216(12):153274. PubMed ID: 33171372
[TBL] [Abstract][Full Text] [Related]
32. Cell cycle control by the insulin-like growth factor signal: at the crossroad between cell growth and mitotic regulation.
Scalia P; Williams SJ; Fujita-Yamaguchi Y; Giordano A
Cell Cycle; 2023 Jan; 22(1):1-37. PubMed ID: 36005738
[TBL] [Abstract][Full Text] [Related]
33. IGF axis and other factors in HPV-related and HPV-unrelated carcinogenesis (review).
Durzyńska J
Oncol Rep; 2014 Dec; 32(6):2295-306. PubMed ID: 25333772
[TBL] [Abstract][Full Text] [Related]
34. Disrupting insulin-like growth factor signaling as a potential cancer therapy.
Sachdev D; Yee D
Mol Cancer Ther; 2007 Jan; 6(1):1-12. PubMed ID: 17237261
[TBL] [Abstract][Full Text] [Related]
35. Disrupting Insulin and IGF Receptor Function in Cancer.
Cao J; Yee D
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33429867
[TBL] [Abstract][Full Text] [Related]
36. Regulation of Runx2 and Its Signaling Pathways by MicroRNAs in Breast Cancer Metastasis.
Pranavkrishna S; Sanjeev G; Akshaya RL; Rohini M; Selvamurugan N
Curr Protein Pept Sci; 2021; 22(7):534-547. PubMed ID: 33200704
[TBL] [Abstract][Full Text] [Related]
37. Unveiling the connection: Long-chain non-coding RNAs and critical signaling pathways in breast cancer.
Thapa R; Afzal O; Gupta G; Bhat AA; Almalki WH; Alzarea SI; Kazmi I; Altamimi ASA; Subramaniyan V; Thangavelu L; Singh SK; Dua K
Pathol Res Pract; 2023 Sep; 249():154736. PubMed ID: 37579591
[TBL] [Abstract][Full Text] [Related]
38. ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.
Tognon CE; Somasiri AM; Evdokimova VE; Trigo G; Uy EE; Melnyk N; Carboni JM; Gottardis MM; Roskelley CD; Pollak M; Sorensen PH
Cancer Res; 2011 Feb; 71(3):1060-70. PubMed ID: 21148487
[TBL] [Abstract][Full Text] [Related]
39. The insulin-like growth factor system as a treatment target in breast cancer.
Yee D
Semin Oncol; 2002 Jun; 29(3 Suppl 11):86-95. PubMed ID: 12138402
[TBL] [Abstract][Full Text] [Related]
40. Long non-coding RNAs XIST and MALAT1 hijack the PD-L1 regulatory signaling pathway in breast cancer subtypes.
Samir A; Tawab RA; El Tayebi HM
Oncol Lett; 2021 Aug; 22(2):593. PubMed ID: 34149904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
